Background: This retrospective single-center cohort study evaluated the efficacy and safety of a combination of neoadjuvant luteinizing hormone-releasing hormone (LHRH) antagonist and tegafur-uracil (UFT) therapy (NCHT) and investigated the medical records of patients with high-risk PCa who underwent robot-assisted radical prostatectomy (RARP). The therapy was followed by RARP for high-risk PCa.

Materials And Methods: The enrolled patients were divided into two groups: low-intermediate-risk PCa patients who underwent RARP without neoadjuvant therapy (non-high-risk) and those who underwent NCHT followed by RARP (high-risk group). This study enrolled 227 patients (126: non-high-risk and 101: high-risk group). Patients in the high-risk-group had high-grade cancer compared to those in the non-high-risk-group.

Results: At the median follow-up period of 12.0 months, there were no PCa deaths; two patients (0.9%) died of other causes. Twenty patients developed biochemical recurrence (BCR); the median time until BCR was 9.9 months after surgery. The 2-year biochemical recurrence-free survival rates were 94.2% and 91.1% in the non-high-risk and high-risk-group, respectively ( = 0.465). Grade ≥3 NCHT-related adverse events developed in nine patients (8.9%).

Conclusions: This study indicates that combining neoadjuvant LHRH antagonists and UFT followed by RARP may improve oncological outcomes in patients with high-risk PCa.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223720PMC
http://dx.doi.org/10.3390/life13051072DOI Listing

Publication Analysis

Top Keywords

patients
9
efficacy safety
8
neoadjuvant luteinizing
8
luteinizing hormone-releasing
8
hormone-releasing hormone
8
antagonist tegafur-uracil
8
patients high-risk
8
high-risk pca
8
rarp high-risk
8
high-risk group
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!